Refining post-blinatumomab risk stratification through ultrasensitive-based measurable residual disease assessment

Authors

Institutions

Publication Details

Journal
Haematologica
Published
2026-04-16
DOI
https://doi.org/10.3324/haematol.2026.300941
Primary Topic
HER2/EGFR in Cancer Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Refining post-blinatumomab risk stratification through ultrasensitive-based measurable residual disease assessment

Ibrahim Aldoss, Yazeed Samara
Haematologica
HER2/EGFR in Cancer Research
article

Refining post-blinatumomab risk stratification through ultrasensitive-based measurable residual disease assessment

Ibrahim Aldoss, Yazeed Samara
article en

Abstract

No abstract available for this paper.
Haematologica
City of Hope (US), Cell Technology (China) (HK)
Zero hunger
Openalex Percentile: Top 23%
HER2/EGFR in Cancer Research
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.